JP2017503482A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017503482A5 JP2017503482A5 JP2016536893A JP2016536893A JP2017503482A5 JP 2017503482 A5 JP2017503482 A5 JP 2017503482A5 JP 2016536893 A JP2016536893 A JP 2016536893A JP 2016536893 A JP2016536893 A JP 2016536893A JP 2017503482 A5 JP2017503482 A5 JP 2017503482A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cytomegalovirus
- nucleotide sequence
- antigenic fragment
- viral vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361911135P | 2013-12-03 | 2013-12-03 | |
| US61/911,135 | 2013-12-03 | ||
| US201462055699P | 2014-09-26 | 2014-09-26 | |
| US62/055,699 | 2014-09-26 | ||
| PCT/EP2014/076466 WO2015082570A1 (en) | 2013-12-03 | 2014-12-03 | Cmv vaccines |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020218641A Division JP7001807B2 (ja) | 2013-12-03 | 2020-12-28 | Ｃｍｖワクチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017503482A JP2017503482A (ja) | 2017-02-02 |
| JP2017503482A5 true JP2017503482A5 (enExample) | 2018-01-18 |
| JP6818551B2 JP6818551B2 (ja) | 2021-01-20 |
Family
ID=52232138
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016536893A Active JP6818551B2 (ja) | 2013-12-03 | 2014-12-03 | Ｃｍｖワクチン |
| JP2020218641A Active JP7001807B2 (ja) | 2013-12-03 | 2020-12-28 | Ｃｍｖワクチン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020218641A Active JP7001807B2 (ja) | 2013-12-03 | 2020-12-28 | Ｃｍｖワクチン |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10111945B2 (enExample) |
| EP (2) | EP3904522A1 (enExample) |
| JP (2) | JP6818551B2 (enExample) |
| CN (2) | CN105980570B (enExample) |
| AU (2) | AU2014359276B2 (enExample) |
| CA (1) | CA2932318C (enExample) |
| CY (1) | CY1124288T1 (enExample) |
| DK (1) | DK3077519T3 (enExample) |
| ES (1) | ES2868427T3 (enExample) |
| HR (1) | HRP20211015T1 (enExample) |
| HU (1) | HUE054579T2 (enExample) |
| LT (1) | LT3077519T (enExample) |
| PL (1) | PL3077519T3 (enExample) |
| PT (1) | PT3077519T (enExample) |
| RS (1) | RS61993B1 (enExample) |
| SI (1) | SI3077519T1 (enExample) |
| WO (1) | WO2015082570A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2604695T3 (pl) | 2007-12-27 | 2023-04-11 | Universität Zürich | Cząstka arenawirusa z defektem replikacji |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| HUE054579T2 (hu) | 2013-12-03 | 2021-09-28 | Hookipa Biotech Gmbh | CMV vakcinák |
| WO2016075250A1 (en) | 2014-11-13 | 2016-05-19 | Université De Genève | Tri-segmented arenaviruses as vaccine vectors |
| EP3031822A1 (en) * | 2014-12-08 | 2016-06-15 | Novartis AG | Cytomegalovirus antigens |
| CA2987155A1 (en) | 2015-06-10 | 2016-12-15 | Hookipa Biotech Ag | Hpv vaccines |
| CA3002922A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| EP4177348A1 (en) * | 2015-11-04 | 2023-05-10 | Hookipa Biotech GmbH | Vaccines against hepatitis b virus |
| ES2922981T3 (es) * | 2015-11-12 | 2022-09-22 | Hookipa Biotech Gmbh | Partículas de arenavirus como vacunas contra el cáncer |
| WO2017156146A1 (en) * | 2016-03-08 | 2017-09-14 | University Of Vermont And State Agricultural College | Modified arenavirus |
| JP7046828B2 (ja) | 2016-04-15 | 2022-04-04 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 滲出型加齢性黄斑変性の治療のための組成物 |
| CA3041307A1 (en) | 2016-10-21 | 2018-04-26 | Giuseppe Ciaramella | Human cytomegalovirus vaccine |
| WO2018083220A2 (en) | 2016-11-04 | 2018-05-11 | Hookipa Biotech Ag | Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines |
| CA3050914A1 (en) * | 2017-01-27 | 2018-08-02 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Vaccine compositions of herpesvirus envelope protein combinations to induce immune response |
| SG11201909361SA (en) | 2017-04-14 | 2019-11-28 | Regenxbio Inc | Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2 sulfatase (ids) produced by human neural or glial cells |
| WO2018204080A1 (en) * | 2017-05-02 | 2018-11-08 | The Scripps Research Institute | Compositions and methods related to arenavirus immunogens |
| CN112512569A (zh) | 2018-05-11 | 2021-03-16 | 希望之城 | 表达多个巨细胞病毒(cmv)抗原的mva载体及其用途 |
| CN113271968B (zh) * | 2018-10-17 | 2024-06-14 | 葛兰素史密丝克莱恩生物有限公司 | 经修饰的巨细胞病毒蛋白和稳定化的复合物 |
| US12290560B2 (en) | 2018-12-10 | 2025-05-06 | Km Biologics Co., Ltd. | Vaccine for preventing or treating congenital infection with cytomegalovirus |
| CA3160032A1 (en) | 2019-11-07 | 2021-05-14 | Universitat Basel | Arenaviruses as vectors |
| KR102837045B1 (ko) * | 2020-06-09 | 2025-07-23 | 케이엠 바이올로직스 가부시키가이샤 | 사이토메갈로바이러스의 gB와 펜타머의 융합 단백질 및 당해 융합 단백질을 포함하는 백신 |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| RU2756557C1 (ru) * | 2020-11-02 | 2021-10-01 | Федеральное государственное бюджетное учреждение "Федеральный центр охраны здоровья животных" (ФГБУ "ВНИИЗЖ") | Способ опосредованного определения титра вируса ящура в неинактивированном сырье для вакцины при амплификации вирусной нуклеиновой кислоты и детекции РНК-ампликонов с применением технологии молекулярных биконов |
| AU2022221284A1 (en) | 2021-02-10 | 2023-08-17 | Regenxbio Inc. | Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids) |
| EP4337320A1 (en) | 2021-05-13 | 2024-03-20 | Hookipa Biotech GmbH | Arenaviruses as vectors |
| WO2024163912A2 (en) * | 2023-02-03 | 2024-08-08 | The Children's Medical Center Corporation | Vaccine and therapeutic protein delivery compositions comprising fusion proteins |
| WO2025056782A1 (en) | 2023-09-15 | 2025-03-20 | Hookipa Biotech Gmbh | Arenavirus formulations, methods and uses thereof |
| CN118221773B (zh) * | 2024-02-05 | 2025-09-09 | 首都医科大学附属北京儿童医院保定医院 | 与HLA相关的CMV pp65表位疫苗组合物与应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| EP0436537A4 (en) * | 1988-01-29 | 1992-04-08 | Chiron Corporation | Recombinant cmv neutralizing proteins |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| JP2003527847A (ja) * | 2000-03-21 | 2003-09-24 | ジェンザイム・コーポレーション | 治療用抗サイトメガロウイルス化合物 |
| DE102004034461B4 (de) * | 2004-07-16 | 2008-02-07 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Gentherapie solider Tumore durch retrovirale, mit Arenavirus-Glykoprotein pseudotypisierte Vektoren |
| EP1856250B1 (en) * | 2005-02-15 | 2013-07-24 | The University of North Carolina At Chapel Hill | New live virus vaccines |
| WO2007109812A2 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Immunopotentiating compounds |
| EP2010537B1 (en) | 2006-03-23 | 2011-12-28 | Novartis AG | Imidazoquinoxaline compounds as immunomodulators |
| PL2604695T3 (pl) * | 2007-12-27 | 2023-04-11 | Universität Zürich | Cząstka arenawirusa z defektem replikacji |
| US8580276B2 (en) * | 2009-06-05 | 2013-11-12 | City Of Hope | Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof |
| US20120093848A1 (en) * | 2009-06-26 | 2012-04-19 | Vectorite Biomedica Inc. | Immunogenic composition comprising peptides derived from cytomegalovirus and the use thereof |
| BR112013008624B1 (pt) * | 2010-10-15 | 2022-07-26 | Glaxosmithkline Biologicals S.A. | Polipeptídeo gb de citomegalovírus (cmv), preparação, composição imunogênica, polinucleotídeo, vetor recombinante, e, microrganismo transgênico |
| CN103597098A (zh) * | 2011-01-07 | 2014-02-19 | 斯洛伐克生物科学公司 | 病毒诊断 |
| WO2012162428A1 (en) * | 2011-05-23 | 2012-11-29 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Prime-boost vaccination for viral infection |
| WO2013006838A1 (en) * | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
| US8834307B2 (en) | 2011-10-06 | 2014-09-16 | Kawasaki Jukogyo Kabushiki Kaisha | Belt type continuously variable transmission |
| WO2013054199A2 (en) * | 2011-10-12 | 2013-04-18 | Novartis Ag | Cmv antigens and uses thereof |
| HK1210037A1 (en) * | 2012-07-06 | 2016-04-15 | Novartis Ag | Complexes of cytomegalovirus proteins |
| WO2014140301A1 (en) | 2013-03-15 | 2014-09-18 | Université De Genève | Anti-mycobacterial vaccines |
| HUE054579T2 (hu) | 2013-12-03 | 2021-09-28 | Hookipa Biotech Gmbh | CMV vakcinák |
| WO2016075250A1 (en) | 2014-11-13 | 2016-05-19 | Université De Genève | Tri-segmented arenaviruses as vaccine vectors |
| CA2987155A1 (en) | 2015-06-10 | 2016-12-15 | Hookipa Biotech Ag | Hpv vaccines |
| EP4177348A1 (en) | 2015-11-04 | 2023-05-10 | Hookipa Biotech GmbH | Vaccines against hepatitis b virus |
| ES2922981T3 (es) | 2015-11-12 | 2022-09-22 | Hookipa Biotech Gmbh | Partículas de arenavirus como vacunas contra el cáncer |
| WO2017198726A1 (en) | 2016-05-18 | 2017-11-23 | Hookipa Biotech Ag | Tri-segmented pichinde viruses as vaccine vectors |
| WO2018083220A2 (en) | 2016-11-04 | 2018-05-11 | Hookipa Biotech Ag | Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines |
| CN110719788A (zh) | 2017-04-07 | 2020-01-21 | 霍欧奇帕生物科技有限公司 | 治疗实体瘤的沙粒病毒颗粒 |
| CA3160032A1 (en) | 2019-11-07 | 2021-05-14 | Universitat Basel | Arenaviruses as vectors |
| JP2023527083A (ja) | 2020-05-29 | 2023-06-26 | ホオキパ バイオテック ジーエムビーエイチ | アレナウイルスベクターを使用するがんの治療方法 |
-
2014
- 2014-12-03 HU HUE14820762A patent/HUE054579T2/hu unknown
- 2014-12-03 US US15/101,363 patent/US10111945B2/en active Active
- 2014-12-03 LT LTEP14820762.4T patent/LT3077519T/lt unknown
- 2014-12-03 RS RS20210759A patent/RS61993B1/sr unknown
- 2014-12-03 EP EP21165671.5A patent/EP3904522A1/en not_active Withdrawn
- 2014-12-03 PL PL14820762T patent/PL3077519T3/pl unknown
- 2014-12-03 JP JP2016536893A patent/JP6818551B2/ja active Active
- 2014-12-03 DK DK14820762.4T patent/DK3077519T3/da active
- 2014-12-03 CA CA2932318A patent/CA2932318C/en active Active
- 2014-12-03 CN CN201480074709.4A patent/CN105980570B/zh active Active
- 2014-12-03 EP EP14820762.4A patent/EP3077519B1/en active Active
- 2014-12-03 CN CN202210602284.6A patent/CN115058452A/zh active Pending
- 2014-12-03 SI SI201431830T patent/SI3077519T1/sl unknown
- 2014-12-03 HR HRP20211015TT patent/HRP20211015T1/hr unknown
- 2014-12-03 AU AU2014359276A patent/AU2014359276B2/en active Active
- 2014-12-03 WO PCT/EP2014/076466 patent/WO2015082570A1/en not_active Ceased
- 2014-12-03 ES ES14820762T patent/ES2868427T3/es active Active
- 2014-12-03 PT PT148207624T patent/PT3077519T/pt unknown
-
2018
- 2018-09-20 US US16/137,323 patent/US11554169B2/en active Active
-
2020
- 2020-12-28 JP JP2020218641A patent/JP7001807B2/ja active Active
-
2021
- 2021-04-26 AU AU2021202541A patent/AU2021202541A1/en not_active Abandoned
- 2021-06-29 CY CY20211100578T patent/CY1124288T1/el unknown
-
2022
- 2022-11-22 US US18/058,116 patent/US20230181725A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017503482A5 (enExample) | ||
| HRP20211015T1 (hr) | Cjepivo protiv citomegalovirusa (cmv) | |
| JP2021061848A5 (enExample) | ||
| JP2021182922A5 (enExample) | ||
| Begum et al. | Challenges and prospects of COVID‐19 vaccine development based on the progress made in SARS and MERS vaccine development | |
| FI3371316T3 (fi) | Rokotteita hepatiitti b -virusta vastaan | |
| TWI605124B (zh) | 新穎桿狀病毒載體及使用方法 | |
| CN113666990B (zh) | 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用 | |
| Mitra-Kaushik et al. | Identification of a cytotoxic T-cell epitope on the recombinant nucleocapsid proteins of Rinderpest and Peste des petits ruminants viruses presented as assembled nucleocapsids | |
| JP2018536433A5 (enExample) | ||
| US12064477B2 (en) | HPV vaccine | |
| JP2017522907A5 (enExample) | ||
| JP2009540801A5 (enExample) | ||
| RU2017113571A (ru) | Рекомбинантные вакцины от fmdv и их применение | |
| HU229101B1 (en) | Dna transfection system for the generation of infectious influenza virus | |
| CN113930452B (zh) | 基于黑猩猩腺病毒载体的重组载体、腺病毒、2019新型冠状病毒疫苗及其制备方法 | |
| Small et al. | Viruses—From pathogens to vaccine carriers | |
| Smith et al. | The development of prophylactic and therapeutic EBV vaccines | |
| JP5675789B2 (ja) | 免疫接種のための発現ベクターとしての水疱性口内炎ウイルスの異なる複数の抗原型 | |
| Li et al. | A single immunization with a recombinant canine adenovirus expressing the rabies virus G protein confers protective immunity against rabies in mice | |
| CN113226364A (zh) | 组合物和方法 | |
| US20230372474A1 (en) | Recombinant hvt and uses thereof | |
| JP2019500320A5 (enExample) | ||
| WO2015024484A1 (zh) | 一种新型狂犬病疫苗及其制备方法 | |
| Galdiero et al. | SARS-CoV-2 vaccine development: where are we |